Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, has become the reference compound for studying pharmacologically driven body-weight reduction. This article examines what the controlled literature actually reports about the durability of that effect, and where the evidence stops.

The research question, framed honestly

“Sustainable” is a demanding word. In metabolic research it implies not just that a compound lowers body weight while it is administered, but that the reduction persists in a stable, reproducible way over extended timeframes and, ideally, after the intervention ends. Semaglutide is one of the most heavily studied molecules against that standard, which makes it a useful case study rather than a settled answer. The controlled literature is unusually deep — a coordinated programme of phase 3 trials, several multi-year extensions, and a large cardiovascular-outcomes study — yet the durability question remains genuinely two-sided. This article walks through what those studies measured, in third-person research terms, and marks clearly where the data support strong statements and where they do not.

Throughout, the framing is experimental. Statements about “weight reduction” describe outcomes recorded in defined trial populations under defined protocols; they are not claims about any individual or about any use of material sold by Qovigen, which is research-use-only.

How semaglutide was engineered from GLP-1

Native GLP-1 is an incretin peptide with a circulating half-life of only a few minutes, because the enzyme dipeptidyl peptidase-4 degrades it almost immediately. That fragility makes the unmodified hormone useless as a long-acting agent. Semaglutide is the product of a deliberate protein-engineering effort to solve exactly that problem.¹ As described in the medicinal-chemistry work that first characterised the molecule, it carries two amino-acid substitutions relative to human GLP-1 — an α-aminoisobutyric acid at position 8 to block enzymatic cleavage, and an arginine at position 34 — and is derivatised at lysine 26 with a fatty di-acid linker.¹

The fatty-acid moiety is the design centrepiece: it drives strong, reversible binding to serum albumin, which acts as a circulating reservoir. Bound peptide is shielded from renal clearance and enzymatic degradation and is released slowly, producing a reported plasma half-life on the order of 46 hours in mini-pig models and, in humans, a duration long enough to justify once-weekly subcutaneous administration.¹ The trade-off engineered into the design was a roughly three-fold reduction in GLP-1 receptor affinity compared with liraglutide, accepted in exchange for the far longer exposure.¹ For researchers, this pharmacokinetic profile matters: steady receptor occupancy across the dosing interval is a precondition for interpreting any downstream metabolic readout, and it is why reconstitution and handling protocols emphasise stability.

Mechanism: how GLP-1R signalling lowers energy intake

The GLP-1 receptor is expressed in the pancreas, the gastrointestinal tract, and — critically for body-weight research — in central nervous system regions that regulate appetite and reward. The mechanistic account of how receptor agonism reduces energy intake rests on several converging pathways rather than a single switch.

Central appetite and satiety signalling

GLP-1 receptors in hypothalamic and hindbrain nuclei participate in the sensing of nutritional state and the generation of satiety. Agonists engaging these circuits are associated in animal models with reduced food intake and increased signalling of fullness.¹¹ Because semaglutide maintains sustained receptor engagement, the mechanistic hypothesis under study is that it shifts the baseline of appetite regulation rather than producing brief, meal-locked suppression.

Reward and food-seeking circuitry

Beyond homeostatic hunger, GLP-1 signalling intersects with the mesocorticolimbic reward system. Site-specific rodent work using the GLP-1 analogue exendin-4 reported that receptor activation in the ventral tegmental area, nucleus accumbens, lateral hypothalamus and dorsomedial hippocampus suppressed motivated responding for palatable food, while some hypothalamic nuclei modulated operant responding for sucrose.¹¹ This body of work is preclinical and uses a related analogue, so it should be read as mechanistic context for the drug class, not as a direct semaglutide result in humans.

Gastric and peripheral contributions

Peripherally, GLP-1 receptor agonism slows gastric emptying, which prolongs the sensation of fullness after a meal and blunts post-prandial glucose excursions. In parallel, the pancreatic actions of the class — glucose-dependent insulin secretion and suppression of glucagon — underlie its original development as a glucose-lowering agent. In body-weight research the central appetite effects are generally regarded as the dominant driver of reduced energy intake, with the peripheral effects contributing to the overall metabolic picture.

What the long-term controlled trials report

The STEP (Semaglutide Treatment Effect in People with obesity) programme provides the core durability evidence. In the STEP 1 trial, participants with overweight or obesity and without diabetes received once-weekly subcutaneous semaglutide 2.4 mg or placebo over 68 weeks alongside lifestyle intervention; the semaglutide group showed a mean body-weight change substantially greater than placebo.² STEP 2 examined the same regimen in adults who also had type 2 diabetes and reported an estimated mean body-weight change of −9.6% with semaglutide 2.4 mg versus −3.4% with placebo at week 68, a treatment difference of −6.2 percentage points.³ STEP 3 paired the compound with intensive behavioural therapy and again reported a significantly larger reduction than placebo.⁴

The single most relevant trial for the “sustainability” question is STEP 5, which extended randomised, placebo-controlled observation to 104 weeks — two years.⁵ The reported outcome was that the separation from placebo was maintained across the second year rather than eroding, which is the strongest controlled evidence available that the effect does not simply fade during continued administration. Parallel trials in a predominantly East Asian population — STEP 6 and STEP 7 — reproduced clinically meaningful reductions versus placebo, supporting reproducibility across differing study populations.⁹¹⁰

Two interpretive cautions apply. First, these are group means: within any trial there is wide dispersion, and a fraction of participants respond weakly. Second, every one of these studies pairs the compound with a lifestyle or behavioural component, so the trials describe the drug-plus-programme package, not the molecule in isolation.

The weight-regain problem after withdrawal

Here the durability story becomes candid. The STEP 4 trial used a withdrawal design: all participants first received semaglutide during a 20-week run-in, then were randomised either to continue or to switch to placebo. Those who continued kept losing or maintained their reduced weight, while those switched to placebo trended back upward — direct randomised evidence that ongoing receptor engagement is doing continuous work.⁶

The STEP 1 trial extension made the point even more plainly. After treatment stopped at week 68, participants were followed for a further year off-drug; the published extension reported that participants regained a large share of the weight they had lost, and that the associated cardiometabolic improvements moved back toward baseline in parallel.⁷ The mechanistic reading is consistent with everything above: semaglutide modifies appetite signalling for as long as it occupies the receptor, and removing the compound removes the modification. In research terms, this positions semaglutide as a tool for studying ongoing pharmacological modulation of energy balance, not as a one-time intervention that resets a set-point. Any experimental design probing “sustainability” must account for this reversibility explicitly.

Signals beyond body weight

The largest single dataset extending the picture beyond the scale is the SELECT trial. It enrolled 17,604 participants aged 45 or older with pre-existing cardiovascular disease and a body-mass index of 27 or greater but no diabetes, randomising them to once-weekly semaglutide 2.4 mg or placebo, with a mean follow-up near 40 months.⁸ A primary composite cardiovascular endpoint — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, a hazard ratio of 0.80 (95% CI 0.72–0.90).⁸ That is a genuine hard-endpoint result in a large population, and it broadened scientific interest in the class from body weight alone toward cardiometabolic biology.

Two honest qualifications belong alongside it. The trial does not resolve how much of the cardiovascular signal is attributable to weight reduction versus weight-independent effects of GLP-1 receptor agonism — that mechanistic partition remains an open research question. And the same trial reported more frequent discontinuation for adverse events in the semaglutide arm (16.6% vs 8.2%), a reminder that tolerability is a real constraint even where efficacy signals are strong.⁸ Researchers comparing incretin-based compounds often position semaglutide alongside dual and triple agonists such as tirzepatide and amylin analogues like cagrilintide when mapping the pharmacology of this rapidly expanding class.

Limitations, variability and tolerability

A fair reading of the evidence has to hold the strong trial results and their limits in the same frame.

Dependence on continued administration

As the withdrawal data show, the effect is contingent on sustained exposure. This is a pharmacological feature, not a failure, but it defines the boundary of the word “sustainable”: durability has so far been demonstrated during continued administration, not after cessation.⁶⁷

Between-subject variability

Response magnitude varies widely between individuals in every trial, and the sources — genetic, physiological, behavioural — are only partly understood. Group means can obscure the sizeable minority who respond weakly, which is exactly why controlled, adequately powered designs remain necessary rather than anecdote.

Tolerability

Across the STEP programme, gastrointestinal effects — nausea, diarrhoea, vomiting and abdominal discomfort — were the most commonly reported adverse events, typically mild to moderate and most prominent during dose escalation.³ In STEP 2, gastrointestinal adverse events were reported in roughly 63% of the 2.4 mg group versus 34% of placebo, illustrating the scale of the signal.³ This tolerability profile shapes real trial adherence and is a standard variable to control for in any experimental protocol.

Taken together, the honest answer to the title question is layered: semaglutide produces large, reproducible, multi-year body-weight reductions while it is administered, with a supporting cardiovascular signal — but the controlled evidence also shows meaningful regain after withdrawal. “Sustainable” is best understood as conditional on continued receptor engagement, and that condition is itself a fertile subject for further study. Laboratories building on this literature frequently work with a single reference compound such as Semaglutide 5 mg to keep pharmacokinetic assumptions constant across experiments.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.